Therma Bright, a leading medical device company, has recently provided updates on Venowave’s permanent Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes, as well as its distribution partners in the United States. These updates mark significant milestones for Venowave, a revolutionary device that offers non-invasive treatment for various vascular conditions.
Venowave is a wearable medical device designed to improve blood circulation in the lower extremities. It utilizes a unique wave-like motion to stimulate blood flow, reducing the risk of blood clots and promoting healing in patients suffering from conditions such as deep vein thrombosis (DVT), venous insufficiency, and lymphedema.
The recent announcement by Therma Bright confirms that Venowave has been assigned permanent CPT and HCPCS codes. CPT codes are used by healthcare professionals to report medical procedures and services to insurance companies for reimbursement purposes. HCPCS codes, on the other hand, are used for billing Medicare and other insurance providers.
The assignment of permanent codes for Venowave is a significant achievement as it streamlines the reimbursement process for healthcare providers and ensures that patients have access to this innovative treatment option. With these codes in place, healthcare professionals can easily bill insurance companies for Venowave treatments, making it more accessible to patients who can benefit from its therapeutic effects.
In addition to the permanent codes, Therma Bright has also made progress in expanding Venowave’s distribution network in the United States. The company has entered into agreements with several reputable distribution partners to ensure widespread availability of Venowave across the country.
These distribution partners will play a crucial role in introducing Venowave to healthcare providers and patients, educating them about its benefits, and facilitating its adoption in various medical settings. By partnering with established distributors, Therma Bright aims to maximize the reach of Venowave and make it readily accessible to patients in need.
The updates provided by Therma Bright highlight the company’s commitment to advancing the availability and adoption of Venowave as a non-invasive treatment option for vascular conditions. With the assignment of permanent CPT and HCPCS codes, healthcare providers can confidently offer Venowave to their patients, knowing that reimbursement will be streamlined.
Furthermore, the expansion of distribution partners in the United States ensures that Venowave will be more widely available, reaching a larger patient population. This is particularly important considering the prevalence of vascular conditions and the need for effective and accessible treatment options.
Therma Bright’s updates on Venowave’s permanent CPT and HCPCS codes, as well as its distribution partners, are positive developments for both healthcare providers and patients. These advancements pave the way for improved access to this innovative medical device, offering hope to individuals suffering from vascular conditions and enhancing their quality of life.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...